Ardana signs agreement with Cytochemia
Ardana, an emerging Edinburgh-based pharmaceutical company, focused on improving human reproductive health, has signed an agreement under which Ardana grants Cytochemia AG exclusive rights to market Striant SR in Germany.
Ardana, an emerging Edinburgh-based pharmaceutical company, focused on improving human reproductive health, has signed an agreement under which Ardana grants Cytochemia AG exclusive rights to market Striant SR in Germany.
Striant SR is a mucoadhesive buccal (gum surface) testosterone replacement therapy for primary and secondary male hypogonadism (i.e. those suffering from a deficiency or absence of testosterone). Striant SR is the first-to-market buccal adhesive tablet and is marketed by Ardana's own sales force in the UK, to urologists and endocrinologists. Cytochemia has considerable experience in Germany selling to the same specialists through their targeted sales force, which has a strong track record in the education of physicians on product usage. Cytochemia has a strong complementary portfolio to Ardana and its product ImmuCyst, which has been on the market for 13 years, is an established agent for the treatment and prevention of superficial bladder cancer. Striant SR presents an excellent strategic fit with Cytochemia's product portfolio and will be an important addition.
Cytochemia expects to launch Striant SR in the German market later this year. Ardana will receive an upfront payment and ongoing revenues for the supply of Striant SR to Cytochemia.
Dr Maureen Lindsay, chief executive of Ardana, said: 'As the biggest and most developed market in Europe for testosterone replacement, Germany is key for Striant SR. In partnering with Cytochemia we believe that the product is in the best hands to ensure a successful introduction there. Striant's novel and efficient delivery of testosterone has received high levels of acceptance from both patients and prescribers.'